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Eosinophil lineage–committed progenitors (EoPs) are phenotypically isolatable in the 
steady-state murine bone marrow. Purified granulocyte/monocyte progenitors (GMPs) gave 
rise to eosinophils as well as neutrophils and monocytes at the single cell level. Within the 
short-term culture of GMPs, the eosinophil potential was found exclusively in cells activating 
the transgenic reporter for GATA-1, a transcription factor capable of instructing eosinophil 
lineage commitment. These GATA-1–activating cells possessed an IL-5R
 
 
 
 
 
CD34
 
 
 
c-Kit
 
lo
 
 
phenotype. Normal bone marrow cells also contained IL-5R
 
 
 
 
 
CD34
 
 
 
c-Kit
 
lo
 
 EoPs that gave rise 
exclusively to eosinophils. EoPs significantly increased in number in response to helminth 
infection, suggesting that the EoP stage is physiologically involved in eosinophil production 
in vivo. EoPs expressed eosinophil-related genes, such as the eosinophil peroxidase and the 
major basic protein, but did not express basophil/mast cell–related mast cell proteases. The 
enforced retroviral expression of IL-5R
 
 
 
 in GMPs did not enhance the frequency of eosinophil 
lineage read-outs, whereas IL-5R
 
 
 
 
 
 GMPs displayed normal neutrophil/monocyte differentiation 
in the presence of IL-5 alone. Thus, IL-5R
 
 
 
 might be expressed specifically at the EoP stage 
as a result of commitment into the eosinophil lineage. The newly identified EoPs could be 
the cellular target in the treatment of a variety of disorders mediated by eosinophils.
 
Eosinophils are rare hematopoietic cells that
normally constitute only 1–3% of peripheral
blood nucleated cells. In tissues, they are found
mainly in the gastrointestinal mucosa. Upon
diverse stimuli, eosinophils or their progenitors
are recruited from the circulation into inflam-
matory sites where they may modulate im-
mune responses by releasing cytotoxic cationic
proteins and a variety of inflammatory cyto-
kines/chemokines (1). Eosinophils play an im-
portant role in defense mechanisms against
parasitic infections, but also are involved in a
variety of allergic reactions and can mediate
tissue damage (2). Hypereosinophilic syndrome
is characterized by persistent eosinophilia with
tissue infiltration (1), and sometimes is fatal
mainly as a result of eosinophil-mediated car-
diac damage (2). Understanding the develop-
mental pathway of eosinophils is critical to
identifying potential therapeutic targets for eo-
sinophil-mediated disorders.
Like other blood cells, eosinophils are de-
rived from hematopoietic stem cells (HSCs).
Although eosinophils are categorized as granu-
locytes together with neutrophils, their origin
remains controversial. For example, they were
found in vitro in single colonies also contain-
ing basophils, erythrocytes, or myelomono-
cytic cells (3–6). However, lineage read-outs
of multipotent progenitors are random, at least
in vitro (7); therefore, it is difficult to define
the origin of cells based on the cell compo-
nents in single cell–derived colonies. Thus, it
is critical to isolate and locate the eosinophil
lineage–committed progenitors (EoPs) in nor-
mal hematopoiesis.
 
The online version of this article contains supplemental material.
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Eosinophil development is supported by a variety of cy-
tokines, including 
 
 
 
c-related cytokines, such as GM-CSF,
IL-3, and IL-5; however, to develop eosinophilia, IL-5 sig-
naling is especially critical (8). Eosinophilia induced by hel-
minth infection or aeroallergen exposure was not observed
in IL-5–deficient mice (9), and is blocked in mice treated
with neutralizing anti–IL-5 antibodies (10). In turn, IL-5
transgenic mice displayed sustained eosinophilia (11, 12).
Therefore, receptors for IL-5 (IL-5R
 
 
 
) should be expressed
in putative EoPs, which enables EoPs to proliferate and dif-
ferentiate in response to IL-5.
Other critical molecules for eosinophil development in-
clude the GATA transcription factors (13). GATA-1 and
GATA-2 are expressed in mature eosinophils as well as in
cells of the megakaryocyte/erythrocyte lineage. In studies
using transformed chicken cell lines, these GATA factors
played a key role in eosinophil differentiation when their ex-
pression was enforced by transfection (14). GATA-1 can
transactivate the major basic protein (MBP; reference 15).
GATA-1–deficient mice lacked eosinophils, and the en-
forced expression of GATA-1 or GATA-2 stimulated the
formation of eosinophil colonies at the expense of gran-
ulocyte/monocyte colonies (16). Furthermore, enforced
GATA-1 expression converted granulocyte/monocyte cells
into the eosinophil as well as the megakaryocyte/erythrocyte
lineages (17, 18). Thus, it is likely that these GATA factors
are expressed in an early stage of eosinophil progenitors to
support their maturation.
In the present study, we identified EoPs from the normal
murine bone marrow using a FACS. By using mice harbor-
ing a reporter for GATA-1 transcription, we found that the
eosinophil potential exclusively exists in a fraction of prog-
eny of granulocyte/monocyte progenitors (GMPs) that acti-
vated the GATA-1 reporter. These cells expressed IL-5R
 
 
 
in addition to immature hematopoietic cell markers, such as
CD34 and c-Kit. Given the expression pattern of these mol-
ecules, we could purify EoPs within the normal murine
bone marrow prospectively.
 
RESULTS AND DISCUSSION
A transgenic GATA-1 reporter marks eosinophil lineage–
committed progenitors downstream of granulocyte/
monocyte progenitors
 
We first evaluated the distribution of the developmental po-
tential into eosinophils in normal hematopoiesis. We previ-
ously identified the earliest lymphoid-committed progenitor
(common lymphoid progenitor [CLP]; reference 19) and the
earliest myeloid-committed progenitor (common myeloid
progenitor [CMP]; reference 20) that represent the choice
point of the lymphoid versus the myeloid lineage decision. In
the myeloid pathway, the GMP and the megakaryocyte/
erythrocyte progenitor (MEP; reference 20) also have been
Figure 1. Eosinophils develop from GMPs together with neutrophils 
and monocytes. (A) Frequency of eosinophil read-outs from purified HSCs 
stem cells or from myeloid- or lymphoid-committed progenitors deter-
mined by limiting dilution assays. (B) Single GMP-derived colony contained 
eosinophils (Eo) and neutrophils (N). (C) Isolation of EoPs within GMP cul-
tures was achieved by using a transgenic GFP reporter for GATA-1 tran-
scription. GFP is expressed in MEPs, but not in GMPs. The eosinophil poten-
tial was found exclusively in the GATA-1–GFP  fraction of day 3 GMP 
progeny that expressed IL-5R  and CD34. (D) Purified day 3 GATA-1–
GFP IL-5R   cells (left) exclusively generated mature eosinophils (right). 
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isolated downstream of CMPs. Development of eosinophils
was evaluated in liquid cultures containing Slf, IL-3, GM-
CSF, IL-5, and IL-9. By limiting dilution assays, 1 in 4 HSCs,
22 CMPs, and 72 GMPs could generate eosinophils in vitro
(Fig. 1 A), whereas no eosinophil progeny was obtained in
 
 
 
10,000 MEPs, CLPs, proB or proT cells (not depicted); this
indicated that the eosinophil potential exists along with the
granulocyte/monocyte differentiation pathway. The higher
frequencies of the eosinophil potential in HSCs and CMPs
compared with GMPs may be because both populations can
generate multiple GMPs in culture (20). In GMP cultures,
eosinophils were found in 14 out of 1,098 single GMP-
derived colonies (Table I). 6 were pure eosinophil colonies; 4
contained neutrophils and eosinophils (Fig. 1 B); and 4 con-
sisted of eosinophils, neutrophils, and macrophages. Colonies
that contained only macrophages and eosinophils were not
found. These data indicate that the eosinophil potential exists
along with the granulocyte/monocyte differentiation pathway
from HSCs, and at least a fraction of GMPs are bipotent for
the eosinophil and the neutrophil lineages.
 
Table I.
 
Results of single GMP cultures
 
Pure eosinophils Neutrophils and macrophages Neutrophils Macrophages Total
 
No eosinophils NA 240 682 162 1,084
Eosinophil-containing wells 6 4 4 0 14
Total 6 244 686 162 1,098
 
Total 1,200 single GMPs were cultured in the presence of Slf, IL-3, GM-CSF, IL-5, and IL-9.  Plating efficiency was 91% (1,098/1,200).  Each colony type was determined by May-
Grünwald Giemsa (MGG) staining.  In case eosinophils were detected in a colony, EoPO transcripts were additionally analyzed by RT-PCR. 
Figure 2. EoPs are prospectively isolatable in the murine bone 
marrow. (A) FACS analysis of the normal bone marrow demonstrated the 
existence of IL-5R  Lin Sca-1 CD34 c-Kitlo EoPs. (B) Purified EoPs were 
blastic cells (left, top), and formed homogenous compact colonies (left, 
middle) that contained only eosinophils (bottom left). The results of the 
methylcellulose colony assay also are shown (top right). Cytokine cocktails 
used in this study contained Slf, IL-3, IL-5, IL-9, GM-CSF, Epo, and Tpo. 
RT-PCR analyses of purified Gr-1 CD11b  neutrophils and progeny of 
EoPs are shown (bottom right). HPRT, hypoxanthine phosphoribosyltrans-
ferase; MPO, myeloperoxidase. (C) FACS analysis of the bone marrow from 
T. spiralis–infected mice. (D) Percentages of EoPs and CMPs plus GMPs in 
the bone marrow of mice with or without T. spiralis infection. 
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GATA-1 is expressed in mature eosinophils, instructs eo-
sinophil commitment at a myeloid progenitor stage (14, 17),
and transactivates MBP (15). Thus, it is possible that EoPs exist
within cells activating GATA-1 transcription. To separate cells
committed to the eosinophil lineage within GMP cultures by
transcriptional activation of GATA-1, we established mice
harboring the transgenic GATA-1 reporter tagged with GFP.
The promoter construct encompasses all three DNase hyper-
sensitive regions and all six GATA-1 exons. In other trans-
genic models, this construct accurately reproduced endoge-
nous GATA-1 transcriptional control (21). Consistent with
our previous RT-PCR data (18), GATA-1–GFP was not de-
tectable in GMPs or CLPs, but increased at a high level in
MEPs (Fig. 1 C). When culturing GMPs with Slf, IL-3, GM-
CSF, IL-5, and IL-9, a small fraction of Lin
 
 
 
 cells expressing
an intermediate level of GFP appeared on day 3 (Fig. 1 C).
Most GATA-1–GFP
 
 
 
 cells in the immature Lin
 
 
 
 fraction ex-
pressed IL-5R
 
 
 
, CD34 (Fig. 1 C), and a low level of c-Kit,
but not Sca-1 (not depicted). Purified GATA-1–GFP
 
 
 
IL-
5R
 
 
 
 
 
 GMP progeny differentiated only into eosinophils (Fig.
1 D) in liquid cultures, whereas day 3 GATA–1-GFP
 
 
 
 GMP
progeny gave rise only to neutrophils and macrophages (not
depicted) in the presence of the cytokine cocktail. These data
strongly suggest that commitment into the eosinophil lineage
completes within 3 d during the GMP culture, and that the
GATA-1–GFP expression marks the vast majority of cells ca-
pable of differentiation into eosinophils within day 3 GMP
cultures. Because Lin
 
 
 
GATA-1–GFP
 
 
 
 cells did not express
IL-5R
 
 
 
 (Fig. 1 C), IL-5R
 
 
 
 was likely to be a useful marker
for EoPs in normal mice. We tried to isolate EoPs in the nor-
mal bone marrow by using this phenotypic definition.
 
Isolation of IL-5R–expressing eosinophil lineage–committed 
progenitors in murine bone marrow
 
In the normal bone marrow, the Lin
 
 
 
Sca-1
 
 
 
CD34
 
 
 
 fraction
contained a small number of cells (
 
 
 
0.05% of total) express-
ing IL-5R
 
 
 
 and a low level of c-Kit (Fig. 2 A). Similar to
GATA-1–GFP
 
 
 
 GMP progeny, purified IL-5R
 
 
 
 
 
Lin
 
 
 
Sca-
1
 
 
 
CD34
 
 
 
c-Kit
 
lo
 
 EoPs were blastic cells with scattered eosin-
ophilic granules (Fig. 2 B, left). As expected, purified EoPs
differentiated exclusively into eosinophils in liquid and meth-
ylcellulose cultures. Single EoPs formed eosinophil colonies at
 
 
 
30% of plating efficiency in methylcellulose containing Slf,
IL-3, IL-5, IL-9, GM-CSF, Epo, and Tpo, or IL-5 alone
(Fig. 2 B). Progeny of EoPs were all eosinophils with IL-
5R
 
 
 
 
 
Gr-1
 
 
 
 phenotype by FACS (not depicted), and pos-
sessed eosinophil peroxidase (EoPO) and MBP, but not my-
eloperoxidase transcripts (Fig. 2 B). Thus, EoPs have the
eosinophil lineage–restricted differentiation capacity, and their
proliferation and maturation can be supported solely by IL-5.
We next considered whether the IL-5R
 
 
 
 
 
Lin
 
 
 
CD34
 
 
 
c-
Kit
 
lo
 
 EoP is involved in the physiological eosinophil develop-
ment in response to inflammation. Mice infected with 
 
Tri-
chinella spiralis
 
 display accumulation of mature eosinophils in
the intestine within 5 d after infection (22). Therefore, we
analyzed the bone marrow of infected mice. On day 5, in the
bone marrow, EoPs expanded by approximately threefold in
number, whereas numbers of GMPs and CMPs were not af-
fected (Fig. 2 C); this suggested that the EoP population rep-
resents a critical stage for in vivo eosinophil development.
Purified EoPs from infected mice again differentiated exclu-
sively to eosinophils (unpublished data). Because we could
not find IL-5R
 
 
 
 
 
Lin
 
 
 
Sca-1
 
 
 
CD34
 
 
 
c-Kit
 
lo
 
 EoPs in the
spleen or the intestine of normal or helminth-infected mice
(unpublished data), these data suggest that eosinophils are
produced mainly in the bone marrow via the EoP stage.
We then analyzed the expression of eosinophil lineage–
related genes in purified EoPs (Fig. 3 A). EoPs expressed
transcription factors critical for eosinophil development, in-
cluding GATA-1, GATA-2, PU.1, and C/EBP
 
 
 
, whereas
GMPs only expressed PU.1 and C/EBP
 
 
 
. The expression
level of GATA-1 in purified EoPs, GMPs, MEPs, Gr-
Figure 3. RT-PCR analyses of lineage-affiliated genes in purified 
EoPs and other myeloid progenitors. (A) Conventional RT-PCR analyses 
of lineage-affiliated genes. Mast, peritoneal mast cells. HPRT, hypoxan-
thine phosphoribosyltransferase. (B) A quantitative real-time PCR assay 
for GATA-1 mRNA. Eo, purified IL-5R  Gr-1  eosinophils; Neutro, 
Gr-1hiCD11bhi neutrophils. 
JEM VOL. 201, June 20, 2005
 
1895
 
BRIEF DEFINITIVE REPORT
 
1
 
 
 
CD11c
 
 
 
 neutrophils, and Gr-1
 
 
 
IL-5R
 
 
 
 
 
 eosinophils was
evaluated by a real-time PCR assay (Fig. 3 B). Consistent
with the GFP level of each progenitor in GATA-1–GFP re-
porter mice (Fig. 1 C), EoPs possessed a low amount of
GATA-1 transcripts, whose level was 
 
 
 
10-fold less than that
in MEPs. Mature eosinophils expressed a further two- to
threefold lower amount of GATA-1 transcripts as compared
with EoPs. The expression pattern of GATA-1 in these pu-
rified cells was consistent with the fact that in a chicken my-
eloblast cell line, the ectopic GATA-1–induced reprogram-
ming into the eosinophil and the megakaryocyte lineages
was associated with intermediate and high levels of GATA-1,
respectively (14). Friend of GATA-1, a transcription fac-
tor that promotes erythroid, but suppresses eosinophil, de-
velopment (23) was expressed in MEPs but not EoPs. EoPs
also expressed genes related to eosinophil functions, such as
MBP and EoPO. Fc
 
 
 
RI
 
 
 
 transcripts were barely detectable
in EoPs. EoPs did not express basophil/mast cell–related
genes, such as murine mast cell protease–1 or –5. Although
previous studies demonstrated the presence of granulocytes
with a hybrid eosinophil/basophil phenotype in patients
who had chronic or acute myelogenous leukemia (24, 25),
these data suggest that the developmental pathway for eosin-
ophils is independent of that for basophils or mast cells at
least after the EoP stage in normal murine hematopoiesis.
 
IL-5R is expressed as a result of commitment into the 
eosinophil lineage
 
The fact that IL-5R
 
 
 
 is expressed in EoPs, but not in the
vast majority of GMPs, suggests that IL-5 targets EoPs to
stimulate eosinophil production in vivo, but it is unclear
whether IL-5 signaling exerts an instructive or permissive ef-
fect on eosinophil development. To test the effect of IL-5
signaling on eosinophil lineage commitment, we retrovirally
transduced the IL-5R
 
 
 
 gene into GMPs. GMPs were in-
fected with GFP-tagged IL-5R
 
 
 
 retroviruses (Fig. 4 A) or
control GFP retroviruses, and GFP
 
 
 
 cells were purified on
day 2. Only purified GFP
 
 
 
 GMPs that were infected with
the GFP–IL-5R
 
 
 
 retrovirus expressed IL-5R
 
 
 
 (Fig. 4 B).
Although control GMPs could not respond to IL-5 to form
colonies, IL-5R
 
 
 
 
 
 GMPs gave rise to a variety of GM-
related colonies in the presence of IL-5 alone, as efficiently as
control GMPs cultured with GM-CSF, IL-3, and IL-5 (Fig.
4 C). Most progeny from IL-5R
 
 
 
 
 
 GMPs cultured with IL-5
alone were neutrophils and macrophages (Fig. 4 D). There
was no increase in frequency of eosinophil development be-
tween control and IL-5R
 
 
 
 
 
 GMPs in these cultures (Fig. 4
E). These data indicate that IL-5 signaling does not instruct
eosinophil lineage commitment at the GMP stage, but can
support proliferation and maturation of myelomonocytic
cells as well as eosinophils. Thus, IL-5R
 
 
 
 expression in EoPs
might occur as a result of eosinophil lineage commitment,
and IL-5 might regulate eosinophil production in vivo after
the completion of the eosinophil lineage fate decision. These
results are consistent with a previous report that the bone
marrow cells of mice that constitutively expressed transgenic
IL-5R
 
 
 
 could form megakaryocyte and GM colonies in the
presence of IL-5 alone (26). In this context, in myelopoiesis,
a high level of serum IL-5 mainly can induce eosinophilia
(11) simply because IL-5R
 
 
 
 is expressed only in EoPs but
not in other myeloid progenitors. Therefore, the treatment
of eosinophilia or hypereosinophilic syndrome with neutral-
izing IL-5 antibodies (27–29) might be effective through in-
hibiting proliferation and maturation of EoPs.
In summary, we have delineated the eosinophil develop-
mental pathway in normal murine hematopoiesis. Eosinophils
developed with neutrophils and monocytes from single
GMPs. EoPs were cells activating GATA-1 at a low level as
compared with MEPs, and were isolatable prospectively
downstream of GMPs as a distinct population with the IL-
5R  Lin Sca-1 CD34 c-Kitlo phenotype. Thus, the eosin-
ophil developmental pathway might diverge from neutrophils
and monocytes at the GMP stage, and result in the formation
of EoPs. The newly identified EoPs and other purified pro-
Figure 4. The enforcement of IL-5 signaling did not affect eosino-
phil lineage read-outs at the GMP stage. (A) The construct of MSCV-
mIL-5R -ires-GFP retrovirus. LTR, long terminal repeat. (B) GMP infected 
with GFP-tagged mIL-5R  retroviruses expressed IL-5R  protein detected 
by anti–mIL-5R  monoclonal antibodies (H7). (C) The effect of IL-5 or 
other cytokines on myeloid differentiation of control-GFP  and IL-5R -GFP  
GMPs. Mac, macrophage. (D) Cells derived from IL-5R -GFP  GMPs in the 
presence of IL-5 alone on day 6. IL-5R -GFP  GMPs generate mainly neu-
trophils and macrophages. (E) Frequency of eosinophil read-outs from 
control-GFP  and IL-5R -GFP  GMPs determined by limiting dilution assays.IDENTIFICATION OF THE EOSINOPHIL PROGENITOR | Iwasaki et al. 1896
genitor populations (19, 20) might be useful in investigating
the mechanism of commitment and differentiation of the eo-
sinophil lineage. EoPs also could be a therapeutic target to
control a variety of eosinophil-related disorders, including al-
lergic diseases and the hypereosinophilic syndrome.
MATERIALS AND METHODS
Mice. C57BL6 mice were purchased from Jackson ImmunoResearch Lab-
oratories. GATA-1–GFP transgenic reporter mice have been developed by
using the promoter construct that encompasses all three DNase hypersensi-
tive regions and all six GATA-1 exons (21). GATA-1–GFP mice were
crossed with C57BL6 mice for eight generations. Mice were bred and main-
tained in the Research Animal Facilities at the Dana-Farber Cancer Institute
or Harvard Medical School, in accordance with institutional guidelines.
Antibodies, cell staining, and sorting. HSCs, CLPs, CMPs, MEPs,
and GMPs were purified as reported elsewhere (19, 20). PE-Cy5–conju-
gated rat antibodies specific for the following lineage markers were used:
CD3 (CT-CD3), CD4 (RM4-5), CD8 (5H10), B220 (6B2), Gr-1 (8C5),
and CD19 (6D5; Caltag). To sort EoPs, bone marrow cells were stained
with biotinylated anti–IL-5R  chain (H7; reference 30), FITC-conjugated
anti-CD34 (RAM34), APC-conjugated anti–c-Kit (2B8; BD Biosciences),
and PE-Cy5–conjugated anti–Sca-1 (D7; eBioscience) monoclonal anti-
bodies and with a lineage cocktail, followed by avidin-PE (Caltag). EoPs
were purified as Lin Sca-1 CD34 IL-5R  c-Kitlo cells with a low level of
side scatter profile. Mature eosinophils were purified as IL-5R  Gr-1 
cells. Dead cells were excluded by propidium iodide staining in a PE-Cy5
channel. All progenitor populations were sorted or analyzed using a double
laser (488 nm/350 nm Enterprise II   647nm Spectrum) high-speed cell
sorter (Moflo-MLS, DakoCytomation). For single cell and limiting dilution
assays, cells were sorted directly into 60-well Terasaki plates or 96-well
plates using an automatic cell deposition unit. Data were analyzed with the
FlowJo software (Treestar, Inc.).
Cultures. For limiting dilution and single GMP culture assays, progenitor
cells were cultured in 96-well or 60-well Terasaki plates with the following
liquid medium; Iscove’s Modified Dulbecco’s Medium (GIBCO BRL) sup-
plemented with 20% FCS, 5   10 5 M 2-mercaptoethanol, sodium pyru-
vate, and antibiotics. Cells in each well were split into two preparations; one
is cytospun with May-Grünwald Giemsa staining, and the other is for pre-
paring total RNA in Trizol reagent (Invitrogen). Eosinophil-containing
wells were determined by the presence of eosinophilic granules on May-
Grünwald Giemsa and of EoPO transcripts. For clonogenic analyses of
EoPs, cells were cultured in a methylcellulose medium (Methocult H4100,
Stem Cell Technologies) supplemented with 30% FCS, 1% BSA, and 2 mM
L-glutamine (Stem Cell Technologies). Each EoP-derived colony was
picked up, and its transcripts were analyzed by RT-PCR. The cytokines
used were: murine Slf (20 ng/ml), IL-3 (20 ng/ml), IL-5 (50 ng/ml), IL-7
(10 ng/ml), IL-9 (50 ng/ml), IL-11 (10 ng/ml), GM-CSF (10 ng/ml), Epo
(2 U/ml), and Tpo (10 ng/ml; R&D Systems). All cultures were incubated
at 37 C in a humidified chamber under 5% CO2.
Retroviral transduction of GMPs. A murine IL-5R  cDNA was sub-
cloned into the XhoI site of MSCV-ires-EGFP vector. An empty vector
was used as control. In brief, FACS-purified GMPs were plated onto a re-
combinant fibronectin fragment-coated culture dish (RetroNectin dish;
Takara), and were cultured for 48 h with 1 ml of the virus supernatant con-
taining Slf (20 ng/ml) and IL-11 (10 ng/ml). GFP  GMPs were purified by
FACS, and were subjected to further analyses.
Analysis of gene expression from total RNA. Total RNA extracted
from 200 cells of each population was subjected to RT-PCR analyses.
Primer sequences and PCR protocols for each specific gene are listed in Ta-
ble S1 (available at http://www.jem.org/cgi/content/full/jem.20050548/
DC1). A quantitative real-time PCR assay for GATA-1 was performed
with ABI PRISM 7700 Sequence Detector. The forward primer was 5 -
CAGAACCGGCCTCTCATCC-3 , the reverse primer was 5 -TAGTG-
CATTGGGTGCCTGC-3 , and the probe was 5 -FAM-CCCAAGAAG-
CGAATGATTGTCAGCAAA-TAMRA-3 . Rodent GAPDH control
reagents (Applied Biosystems) were used as an internal control.
Infection with T. spiralis. Infectious larvae (L1) were isolated from the
skeletal muscle of infected mice. The larvae were washed by low-speed
centrifugation (50 g for 5 min), and adjusted to  2,000 larvae per ml. Mice
were infected with  400 larvae each by gavage.
Online supplemental material. Table S1 provides PCR primer sequences
and protocols that were used in Figs. 2 and 3. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050548/DC1.
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